

# Interim report Q1, 2021.

## JANUARY - MARCH 2021

- EBITDA equalled SEK 3,5 million (2,8).
- Operating profit (EBIT) is SEK 0,78 million (0,18)
- Net sales in the period amounted to SEK 30,4 million (38,7)
- Profit after tax amounted to SEK 1,04 million (0,4)
- Earnings per share amounted to SEK 0,09 (0,74) per share

## COVID-19 UPDATE

The pandemic has had a slow-down effect on the Company's sales of APIs as several regions at the beginning of the quarter continued to experience difficulties in supply and demand. Magle Chemoswed continues to adapt to the on-going challenges presented by the pandemic to deliver operationally for the benefit of our customers and patients.

## EVENTS DURING THE REPORTING PERIOD

- The acquisition PharmaCept was closed expanding the Company's reach into direct sales
- The Company filed for a manufacturing license extension for the manufacture of sterile drug products

## EVENTS AFTER THE REPORTING PERIOD

- In April the Company was audited by a European Notified Body and the Company renewed its operating license for ISO13485:2016 for the development and manufacture of medical devices and in-vitro devices.

## KEY FIGURES Q1

	Jan-Mar 2021	Jan-Mar 2020	Full Year 2020
Net sales, TSEK	30 429	38 793	142 337
EBITDA, TSEK	3 538	2 855	16 193
EBITDA margin, %	12%	7%	11%
Operating profit, TSEK	784	187	4 526
Net profit/loss for the period, TSEK	1 004	410	1 819
Earnings per share, SEK*	0,094	0,745	0,240
Operating cash flow, TSEK	3 683	8 636	-5 545
Operating cash flow per share, SEK	0,35	15,7	-0,54
Equity ratio, %	64%	58%	58,8%
Equity at period end, TSEK	137 271	113 516	116 121
Net debt, TSEK	-13 441	-5 065	-33 902

\*Based on the average numbers of shares. See page 9



## CEO COMMENT.

---

**It was, as expected, a challenging start to the year and we have ended the first quarter strongly. We continue to deliver on our strategic priorities and remain very focused on creating significant value for shareholders. We are making substantial progress in our development pipeline to expand our product portfolio on our technology platform. With the upcoming addition of PharmaCept in 2021, I am confident that we are well on our way to building a solid foundation to bring our technology products to the market in an expedited manner.**

Our first-quarter results are in line with our forecasts and mirror the expected impacts of COVID-19. We continue to expect a stable performance over the remainder of the year in line with the outlook for 2021. The CE marking of SmartPan® and SmartGel are vital milestones as we continue to strengthen our mid-term growth prospects through our technology platform-based products. Expansion plans are also well underway to introduce these two products to the market, and we look forward to bringing PharmaCept into the Magle Chemoswed Group as the next step in the company's growth phase. PharmaCept's direct sales and marketing strength will be invaluable to our technology products' direct sales and marketing in the future.

In 2021 we will increase investment in our pipeline, leveraging our technology platform. We will build on our key growth drivers in the contract development and manufacturing (CDMO) space, complete our readiness program to launch SmartPan® and SmartGel and establish our direct sales and marketing presence. Assuming healthcare systems and customer demands approach normality in the latter parts of 2021, we continue to expect to meet our targets for 2021.

For our active pharmaceutical ingredients manufacturing business, we anticipated disruption during the first half of the year, given the COVID-19 impact on demand and supply chain management generally. We expected this disruption to parts of our

portfolio, which is reflected in our first-quarter 2021 manufacturing performance. I am encouraged by the rate at which COVID-19 vaccinations are being made available in many countries, providing a positive indicator for healthcare systems to be returning to normal in 2021. Consequently, I remain confident in the underlying demand for our active pharmaceutical products in the second half of the year.

The strength in demand in the CDMO service segment in the early part of 2021 creates opportunities for us for the latter parts of the year and into 2022. We are experiencing a more significant customer demand than we have experienced previously. This demand is a positive signal for the growth potential in the CDMO service area of the business. Our application to the Swedish Medicines Agency to extend our good manufacturing practice licence to develop and manufacture sterile drug products is expected to fuel this high demand. The investments made to support sterile drug products are expected to increase interest in the service from pharmaceutical companies worldwide seeking to secure CDMOs with these capabilities.

**Justin Pierce (CEO)**



# Manufacturing.

We undertake GMP and ISO manufacturing with a broad range of chemistries at all scales required for Pre-Clinical, Phase I, II, III studies and commercial supply. Our in-house analytical and quality control teams support our manufacturing operations, ensuring the highest quality.

---

Demand in the API portfolio was lower than sales in the same period last year. The reduction in customer demand was anticipated as the consequences of COVID has impacted the territories in which our customers are active. Despite the slow down in need, the reduction was in line with expectations for the period. Currency fluctuations also had a negative revenue contribution in comparison to the same period for 2020. The positive impact of agreements with our raw material suppliers and benefits from negotiations in late 2020 have delivered a lower cost of goods sold in 2021 (3,9) compared to 2020 (13,6). Clinical materials supply was as expected, with customers being supported with materials to conduct their clinical trials.

## JANUARY - MARCH 2021

Sales for the period showed a decrease compared with the corresponding period last year, reducing to SEK 11,9 million compared to SEK 20,9 million in 2020. The lower demand was forecast and anticipated for the period. The customer base on the API supply side remains constant, and the business is not experiencing customer loss. New territorial registrations are ongoing in China and Denmark and are under discussion in Russia to extend the reach and sales on the existing API portfolio. Exclusive contract manufacturing of customer-owned APIs is following forecast.





# Services.

We have a highly experienced and flexible team dedicated to our service offerings. We offer a full range of development services covering the development chain for pharmaceuticals and medical devices. With over 70 years of combined experience, we have a rich history in successfully providing development services.


---

Our integrated group of scientists provides a seamless transition for API and drug substances from the program's initial discovery stages to more in-depth process development. Our teams have extensive experience in route or step rebuild, process optimization and impurities assessment and synthesis. Provision of services in the analysis and process development of drug and medical device candidates on a contract services basis provides ongoing revenues. In 2021 we have increased our capabilities and service offerings to drive growth, focusing on profitability as part of our Value Creation 2024 initiative. Demand for services is high, with the initiation of two new projects in the period. The need for development and analytical services remains intense, with several requests for proposals received.

## JANUARY - MARCH 2021

Demand for development and support services remained high in the period both in new and existing projects. Sales for the period showed an increase of 5% compared with the corresponding period last year, increasing to SEK 9,8 million compared to SEK 9,4 million in 2020. The overall demand is growing, and the opportunities in the CDMO services remains strong.





# Technology product and royalty.

As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.


**EmboCept™** is an embolic agent made up of microspheres in a solution used to treat inoperable liver and lung tumours. Vascular embolization is when an embolic agent is injected into the blood vessel to close the blood vessels and stop the blood flow to a targeted tumour area. The product is marketed across Europe, Israel and Singapore. The plan to increase market share by registering the product into new territories is well underway.

**SmartPan™** is a first in class medical device product designed to detect pancreatic fluid leakage during surgical procedures. Pancreatic fluid detection during surgical procedures provides an assurance of a minimised risk to patients from surgical complications arising from pancreatic fluid leakage. The product was

approved for sale in Europe (CE marked) in January 2021 and will be rolled out in collaboration with Heidelberg University Hospital before entering into commercial sales in Europe.

**SmartGel** is a non-allergenic hydrogel based on the company's microsphere technology. The gel delivers moisture to the wound, whilst maintaining enough absorption capacity for exudate, debris and bacteria. The product received approval for marketing in Europe in January 2021 and is in the pre-marketing phase.

**Royalties** are received quarterly from Becton Dickinson for an out-license agreement for rights to the company technology. In the period of January - April 2021 the royalty received was SEK 7,7 million (6,7).





# Near-term pipeline.

We have a dedicated and highly experienced research and development team that is supported through the integration of the services we offer as a company. Our development is expedited due to our ability to develop in parallel with analytic, formulation and manufacturing expertise.

**1. EmboCept™M** is an embolic agent made up of microspheres in solution used for the treatment of benign prostatic hyperplasia also called prostate enlargement, which is a noncancerous increase in size of the prostate gland. The product is designed for prostatic artery embolization which is a minimally invasive treatment that helps improve lower urinary tract symptoms caused by a benign prostatic hyperplasia. The product is in late stage validation and is being prepared for regulatory filing in 2021.

**2. EmboCept™L** is an embolic agent made up of microspheres in solution used for the treatment of uterine fibroids which are noncancerous growths of the uterus that often appear during

childbearing years. Uterine fibroid embolization is a non surgical way of treating fibroids by blocking off the arteries that feed the fibroids, the uterine arteries, and making the fibroids shrink. The product is in late stage design verification and is being prepared for validation in 2021.

**3. SmartBone** is a combination formulation of microspheres and active ingredients for use in hard tissue procedures where patients need remodeling to the patient's own bone and to ensure that bone growth is supported and sustained through a microsphere matrix that is full bio-compatible and bio-degradable. The product is in the conceptualization stage and will be further developed through the design and development phase in 2021.

The company's near-term pipeline builds on the EmboCept brand than can be expedited to the market. The pipeline also includes candidates for new markets.

Candidate	Phase 1 Ideation	Phase 2 Conceptualisation	Phase 3 Design & Development	Phase 4 Design Verification	Phase 5 Design Validation
<b>EmboCept M</b> Embolisation microsphere for Benign Prostatic Hyperplasia	→				
<b>EmboCept L</b> Embolisation microsphere for Uterine Fibroids	→				
<b>SmartBone</b> Bone repair matrix at implant sites	→				



# Financial overview Q1, 2021.

## net sales

Net sales in the period amounted to SEK 30,4 million (38,8) a period decrease of 22%. The API revenues decreased by 43% to SEK 11,9 million (20,9). Sales in CDMO services increased by 5% to SEK 9,8 (9,4). Medical device sales were at TSEK 978 (1 697). The technology royalties for the period were SEK 7,8 million (6,8).

## raw materials and consumables

Raw materials and consumables amounted to SEK 3,9 million (13,6), which resulted in a gross margin of 87% (65).

## other external expenses

Other external expenses amounted to SEK 8,9 million (8,3). External costs include costs associated with the share issue due to purchase of PharmaCept GmbH.

## personnel costs

Staff costs totaled to SEK 15 (16,6). Personnel costs decreased by 5% due to reduction of employees and a salary increase due to the collective agreement.

## other operating income, expenses

Other operating income and expenses consisted mainly of sales of media to neighboring business, and government founded projects and contribution for employees. Other operating income amounted to TSEK 966 (2 569) and other operating expenses amounted to SEK 0 (0) for the quarter.

## operating result

Operating profit amounted to SEK 0,78 million (0,19).

## net financial items

Net financial items amounted to SEK 0,5 million (-0,35).

## net profit/loss for period

For the reasons explained above, the profit/loss for the fourth quarter amounted to SEK 1 million (0,41), which corresponds to earnings per share of SEK 0,094.

Financial Position	Jan.-Mar. 2021	Jan.-Mar. 2020
TSEK		
Cash & cash equivalents	24 014	2 386
Interest-bearing debt	37 456	33 818
Net debt	-13 441	-31 423
Equity	137 271	116 223

Cashflow	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
TSEK			
Operations	3 683	1 106	12 296
Investing activities	-2 852	-1 915	-6 583
Financing activities	17 061	-99	-3 271



# Condensed consolidated Magle Chemoswed Group income statement

	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
<b>TSEK</b>			
<b>Revenues</b>			
Net sales	30 429	38 793	142 337
Other revenues	966	2 569	3 914
<b>Total</b>	<b>31 396</b>	<b>41 362</b>	<b>146 252</b>
<b>Raw materials and consumables</b>			
	-3 912	-13 627	-30 395
<b>Other external expenses</b>			
	-8 943	-8 296	-40 801
<b>Personnel costs</b>			
	-15 004	-16 584	-58 859
<b>Depreciation and amortization</b>			
	-2 754	-2 668	-11 667
<b>Other operating expenses</b>			
	0	0	-3
<b>Total operating expenses</b>	<b>-30 612</b>	<b>-41 175</b>	<b>-141 726</b>
<b>Operating profit/loss</b>	<b>784</b>	<b>187</b>	<b>4 526</b>
<b>Profit/loss from financial items</b>			
	496	443	706
Financial expenses	0	-92	-2 798
<b>Profit before tax</b>	<b>1 280</b>	<b>538</b>	<b>2 434</b>
<b>Taxes for the period</b>	<b>-276</b>	<b>-128</b>	<b>-614</b>
<b>Net profit/loss for the period</b>	<b>1 004</b>	<b>410</b>	<b>1 819</b>

# Condensed consolidated Magle Chemoswed Group statement of comprehensive income

	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
<b>TSEK</b>			
<b>Profit/loss for the period</b>	<b>1 004</b>	<b>410</b>	<b>1 819</b>
<b>Total comprehensive income for the period</b>	<b>1 004</b>	<b>410</b>	<b>1 819</b>

## Earnings per share

	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
<b>Equity holders of the parent</b>			
Earnings per share before dilution, share issue	0,10	820	3 638
Earnings per share after dilution*, share issue**	0,09	0,75	0,24
Profit/loss for the period	1 004	410	1 819
<b>Average number of shares, thousands</b>			
Average number of shares before dilution, share issue	10 000	0,5	0,5
Average number of shares after dilution, share issue	10 655	550	7 671

\*A share split was carried out on the 27th of March 2020, \*\*A share issue was carried out on the 4th of January 2021

## Condensed consolidated Magle Chemoswed group balance sheet

	March 2021	March 2020	Full Year 2020
<b>TSEK</b>			
<b>ASSETS</b>			
Intangible assets	28 966	27 159	28 966
Tangible assets	103 175	102 102	104 029
Deferred tax asset	0	1 494	2
Other non-current assets	55	55	55
<b>Total non-current assets</b>	<b>132 162</b>	<b>130 810</b>	<b>133 052</b>
Inventories	18 093	16 773	18 348
Trade receivables	21 750	17 634	26 271
Other operating receivables	16 858	29 150	14 272
Cash and cash equivalents	24 014	2 683	6 122
<b>Total current assets</b>	<b>80 715</b>	<b>66 240</b>	<b>65 013</b>
<b>TOTAL ASSETS</b>	<b>212 877</b>	<b>197 050</b>	<b>198 065</b>
<b>EQUITY AND LIABILITIES</b>			
Equity attributable to equity holders of the parent	<b>137 271</b>	<b>113 516</b>	<b>116 121</b>
Liabilities to credit institutions	28 938	4 688	28 938
Leasing debt	2 923	2 546	3 302
Deferred tax liability	2 119	3 676	2 087
<b>Total non-current liabilities</b>	<b>33 980</b>	<b>10 910</b>	<b>34 326</b>
Liabilities to credit institutions	8 518	3 060	11 086
Leasing debt	1 502	1 858	1 494
Trade payables	8 427	20 907	12 365
Other operating liabilities	23 179	46 799	22 672
<b>Total current liabilities</b>	<b>41 627</b>	<b>72 624</b>	<b>47 617</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>212 877</b>	<b>197 050</b>	<b>198 065</b>

## Consolidated Magle Chemoswed Group statement of changes in equity

	Share capital	Other paid in capital	Translation reserves	Retained earnings incl. P/L for year	Total equity
TSEK					
As at 1 January 2020	50	98 927	0	14 682	113 659
Profit/loss as at 31 December 2020				1 819	1 819
Fond emission	450			-450	
Other comprehensive income as at 31 December 2020				643	643
<b>Equity as at 31 December 2020</b>	<b>500</b>	<b>98 927</b>	<b>0</b>	<b>16 694</b>	<b>116 121</b>
As at 1 January 2021	500	98 927	0	16 694	116 121
Profit/loss as at 31 March 2021				1 004	1 004
Other comprehensive income as at 31 March 2021: Translation difference			146		146
Share issue				20 000	20 000
<b>Equity as at 31 March 2021</b>	<b>500</b>	<b>98 927</b>	<b>146</b>	<b>37 698</b>	<b>137 271</b>

## Consolidated Magle Chemoswed Group statement of cashflows

	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
TSEK			
<b>Operating profit/loss</b>	784	186	4 526
Adjustments for depreciation, amortisation and other non-cash items:	-515	2 421	8 610
Changes in working capital	3 414	6 029	-19 910
<b>Net cash flow from operating activities</b>	<b>3 683</b>	<b>8 636</b>	<b>-6 775</b>
Payment of Acquisition of subsidiary company	-1 483	0	-5 904
Investments in assets	-1 369	-1 915	-7 948
<b>Net cash flows from investing activities</b>	<b>-2 852</b>	<b>-1 915</b>	<b>-13 852</b>
Debt incurred	0	0	25 313
Amortisation of bank loan	0	-7 268	-1 125
Amortisation of leasing	-371	-379	-2100
Change in bank overdraft	-2 568	316	724
Shareholders contribution	20 000	0	643
<b>Net cash flow from financing activities</b>	<b>17 061</b>	<b>-7 331</b>	<b>23 455</b>
<b>Net cash flow</b>	<b>17 892</b>	<b>-610</b>	<b>2 828</b>
Cash and cash equivalents at beginning of period	6 122	3 294	3 294
<b>Cash and cash equivalents at end of period</b>	<b>24 014</b>	<b>2 684</b>	<b>6 122</b>



## Parent company income statement

	Jan.-Mar. 2021	Jan.-Mar. 2020	Full Year 2020
<b>TSEK</b>			
Intercompany revenue	1 494	0	1 186
Other revenues	0	74	1 173
<b>Total</b>	<b>1 494</b>	<b>74</b>	<b>2 359</b>
Other external expenses	- 1 814	-153	-3 924
Personnel costs	-1	-1 153	-1 203
<b>Operating profit/loss</b>	<b>-320</b>	<b>-1 232</b>	<b>-2 768</b>
Net financial items	295	-8	-375
<b>Profit loss after financial items</b>	<b>-25</b>	<b>-1 240</b>	<b>-3 143</b>
Group contribution	0	0	3 033
Taxes for the period	5	0	-0
<b>Net profit/loss for the period</b>	<b>-20</b>	<b>-1 240</b>	<b>-110</b>

## Parent company balance sheet

	March 2021	March 2020	December 2020
<b>TSEK</b>			
<b>ASSETS</b>			
Non-current assets	44 647	44 645	44 467
Other receivables	45 762	132 836	45 636
Prepaid expenses	187	11 983	33
Cash and cash equivalents	13 558	219	0
<b>TOTAL ASSETS</b>	<b>104 154</b>	<b>177 806</b>	<b>90 316</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Restricted equity	500	50	500
Unrestricted equity	91 346	69 590	71 366
<b>Total equity</b>	<b>91 846</b>	<b>70 090</b>	<b>71 866</b>
<b>Current liabilities</b>	<b>12 308</b>	<b>107 716</b>	<b>18 451</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>104 154</b>	<b>177 806</b>	<b>90 316</b>

## note 1

### GENERAL INFORMATION, ACCOUNTING PRINCIPLES

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The parent company's reporting has been prepared in accordance with RFR 2, Reporting for Legal Entities, and the Swedish Annual Accounts Act. Accounting principles have been applied as reported for the Annual Report per 31 December 2019. New or amended standards or interpretations of standards effective as of 31 March 2021 have not had any significant impact on Magle Chemoswed's financial statements.

## note 2

### SIGNIFICANT RISKS AND UNCERTAINTIES

The Group is exposed to various financial risks. The business is impacted by many factors that could affect the Group's result and financial position. It is Magle Chemoswed's strategy to continuously identify and manage risks. Financial risk management is described in the Prospectus.

## note 3

### TRANSACTIONS WITH RELATED PARTIES

The financial reports include costs related to the following transactions between Magle Chemoswed and related parties.

Related Party	Service	March 2020	Full Year 2020
Crowberry Group AB (Hedda Lidgard, board member)	Consultancy	0 (TSEK)	630 (TSEK)

## note 4

### FINANCIAL ASSETS AND LIABILITIES

Fair values of current financial assets and liabilities are assessed agree with values accounted for.

## note 5

### SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function responsible for allocating resources and assessing the performance of the operating segments. In the Magle Chemoswed Group, the CEO has been identified as the chief operating decision maker who evaluates the Group's financial position and performance and makes strategic decisions. The CEO analyzes and monitors the business performance based on the Group as a whole. The assessment is thus that the Group's operations consist of one operating segment.

By nature of income	Jan.- Mar. 2021	Jan.- Mar. 2020	Full Year 2020
<b>TSEK</b>			
API revenues (Manufacturing page 3)	11 893	20 936	72 513
Services revenues (Services page 4)	9 794	9 361	35 780
Medical device (Manufacturing page 3)	978	1 697	3 087
License revenues (Technology Product and Royalty page 5)	7 763	6 799	30 957
<b>Total</b>	<b>30 429</b>	<b>38 793</b>	<b>142 337</b>

By country	Jan.- Mar. 2021	Jan.- Mar. 2020	Full Year 2020
<b>TSEK</b>			
Sweden	6 463	2 107	23 960
Europe excluding Sweden	16 061	12 323	37 717
Other territories	7 905	24 363	80 660
<b>Total</b>	<b>30 429</b>	<b>38 793</b>	<b>142 337</b>

By company	Jan.- Mar. 2021	Jan.- Mar. 2020	Full Year 2020
<b>TSEK</b>			
Magle Chemoswed AB	29 513	37 300	137 849
Magle Chemoswed Holding AB	0	0	0
Adroit Science AB*	916	1 493	4 488
<b>Total</b>	<b>30 429</b>	<b>38 793</b>	<b>142 337</b>

\*Adroit Science revenues have been largely incorporated into the Magle Chemoswed AB operational business.



# Definitions.

Magle Chemoswed uses Alternative Performance Measures (APM) to enhance understandability of the information in the financial reports, both for external analysis and comparison and internal performance assessment.

Alternative Performance Measures are key figures not defined in financial reports prepared according to IFRS. The following key figures are used:

## sales growth

The difference in net sales between two periods in relation to net sales for the earlier period. Shows the operations sales performance.

## interest bearing debt

Borrowings from banks, financial institutions and lease liabilities, short and long term. Shows the debt level of the group and forms the base for interest expenses.

## net debt

Interest bearing debt minus cash and cash equivalents. Shows the group's net debt and is used to measure the leverage level of the group and future funding needs.

Sales Growth	Jan.- Mar. 2021	Jan.- Mar. 2020	Full Year 2020
Net sales, TSEK	30 429	38 793	142 337
Sales growth, %	-27%	19%	10%
Gross profit, TSEK	26 517	25 166	111 942
Gross margin, %	87%	65%	79%

Indicators	Jan.- Mar. 2021	Jan.- Mar. 2020	Full Year 2020
Non-current borrowings, TSEK	28 938	4 688	28 938
Current borrowings, TSEK	8 518	3 060	11 086
Interest bearing debt, TSEK	37 456	7 748	40 024
Cash and cash equivalents, TSEK	24 014	2 683	6 122
Net debt, TSEK	-13 441	-5 065	-33 902



## note 6

### NUMBER OF SHARES

Ordinary Shares	Number of shares	Potential shares
31 December 2019	500	
30 June 2020	10 000 000	225 000
4 January 2021	10 800 000	225 000

Share split was made on 27th of March 2020, share issue on 4th of January 2021.

## note 7

### WARRANTS

At period end, there is one warrant program. The warrant program was executed in 2020. Warrants give the holder the right to acquire 1 ordinary share.

Warrant program	Number of options	Equals number of shares
Balance January 1, 2020	0	
Balance March 30, 2020	0	
Balance June 30, 2020	225 000	225 000
Balance December 31, 2020	225 000	225 000

## DECLARATION OF THE BOARD OF DIRECTORS AND THE CEO

The undersigned Board members assure that this Interim report provides a true and fair view of the development of the Group's and Parent Company's operations, position and performance as well as describing material risks and uncertainties faced by the companies being part of the Group. This interim report has not been reviewed by the Company's auditors.



Hans Henrik Lidgard (Chair)



Sven Christer Nilsson



Mats Pettersson



Malin Malmsjö



Hedda Lidgard



Joel Eklund



Justin Pierce (CEO)



Ingela Fritzon



Simon Mårtensson

### Malmö May 14, 2021

This information is information that Magle Chemoswed Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above 2020-07-14, at. 07.00.

## FORTHCOMING DISCLOSURES OF INFORMATION

FINANCIAL CALENDAR	DATE
ANNUAL GENERAL MEETING	18TH MAY, 2021
INTERIM REPORT Q2, 2021	17TH AUGUST, 2021
INTERIM REPORT Q3, 2021	16TH NOVEMBER, 2021
FULL-YEAR AND INTERIM REPORT Q4, 2021	25TH FEBRUARY, 2021

## CONTACT INFORMATION

Justin Pierce, CEO, phone +46 (0)70 593 58 21, [justin.pierce@maglechemoswed.com](mailto:justin.pierce@maglechemoswed.com)

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.